MacroCure Ltd. (NASDAQ:MCUR) has been given an average broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.
Zacks has also given MacroCure an industry rank of 71 out of 265 based on the ratings given to its competitors.
Shares of MacroCure (NASDAQ:MCUR) opened at 1.674 on Monday. The firm’s market cap is $29.64 million. MacroCure has a 52-week low of $0.75 and a 52-week high of $3.20. The stock’s 50 day moving average price is $1.61 and its 200-day moving average price is $1.45.
MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.